Weekly Paclitaxel Dose for Breast Cancer
For breast cancer, the standard weekly paclitaxel dose is 80 mg/m² administered intravenously over 1 hour on days 1,8, and 15 of a 28-day cycle, typically given for 12 weeks (4 cycles) following anthracycline-based chemotherapy in the adjuvant setting.
Standard Dosing Regimens
Adjuvant Setting
The FDA-approved and guideline-supported regimen for adjuvant treatment of node-positive breast cancer is paclitaxel 80 mg/m² IV over 1 hour weekly for 12 weeks (given on days 1,8, and 15 every 28 days for 4 cycles), administered sequentially after 4 cycles of doxorubicin-cyclophosphamide 12. This weekly schedule has demonstrated superior efficacy compared to every-3-week dosing in multiple trials 3.
Metastatic Setting
For metastatic breast cancer after failure of initial therapy, the FDA label recommends 175 mg/m² IV over 3 hours every 3 weeks 1. However, weekly dosing at 80-100 mg/m² on days 1,8, and 15 every 28 days is widely used in clinical practice and supported by research evidence showing comparable efficacy with reduced toxicity 4567.
HER2-Positive Disease
When combined with trastuzumab, use paclitaxel 80 mg/m² weekly with trastuzumab administered concurrently 28. For neoadjuvant therapy with dual HER2 blockade (trastuzumab-pertuzumab), paclitaxel 80 mg/m² on days 1 and 8 every 3 weeks for 6 cycles with carboplatin AUC 5 is an acceptable regimen 9.
Dose Adjustments for Hepatic Dysfunction
Critical: Patients with hepatic impairment require dose reduction based on transaminase and bilirubin levels 1.
For 3-Hour Infusion:
- Normal liver function (transaminases <10× ULN, bilirubin ≤1.25× ULN): 175 mg/m²
- Mild dysfunction (transaminases <10× ULN, bilirubin 1.26-2.0× ULN): 135 mg/m²
- Moderate dysfunction (transaminases <10× ULN, bilirubin 2.01-5.0× ULN): 90 mg/m²
- Severe dysfunction (transaminases ≥10× ULN or bilirubin >5.0× ULN): Not recommended
For 24-Hour Infusion:
- Normal/mild (transaminases <2× ULN, bilirubin ≤1.5 mg/dL): 135 mg/m²
- Moderate (transaminases 2-<10× ULN, bilirubin ≤1.5 mg/dL): 100 mg/m²
- Moderate-severe (transaminases <10× ULN, bilirubin 1.6-7.5 mg/dL): 50 mg/m²
- Severe (transaminases ≥10× ULN or bilirubin >7.5 mg/dL): Not recommended
Dose Modifications for Toxicity
Neutropenia
- Do not initiate or repeat treatment unless neutrophil count ≥1,500 cells/mm³ (≥1,000 cells/mm³ for AIDS-related Kaposi's sarcoma) 1
- Reduce dose by 20% for subsequent cycles if severe neutropenia (neutrophils <500 cells/mm³ for ≥1 week) occurs 1
Peripheral Neuropathy
- Reduce dose by 20% for subsequent courses if severe peripheral neuropathy develops 1
- Grade 3 neuropathy is a clear indication for dose reduction; consider discontinuation if it persists despite reduction
Thrombocytopenia
- Do not treat unless platelet count ≥100,000 cells/mm³ 1
Premedication Requirements
All patients must receive premedication to prevent severe hypersensitivity reactions 1:
- Dexamethasone 20 mg PO at 12 and 6 hours before paclitaxel
- Diphenhydramine 50 mg IV 30-60 minutes before paclitaxel
- H2 antagonist (cimetidine 300 mg or ranitidine 50 mg IV) 30-60 minutes before paclitaxel
Clinical Considerations
Weekly dosing (80 mg/m²) offers advantages over every-3-week schedules: reduced myelosuppression, less severe neuropathy, and comparable or superior efficacy 73. The dose-dense approach with weekly administration achieves higher dose intensity while maintaining tolerability.
For elderly patients (≥65 years) or those with poor performance status, weekly paclitaxel 80 mg/m² is particularly appropriate, as it demonstrates substantial activity with a favorable toxicity profile 56.
Common pitfall: Failing to adjust doses for hepatic dysfunction can lead to severe myelosuppression. Always check liver function tests before each cycle and adjust accordingly.
Duration of therapy: In the adjuvant setting, complete 12 weekly doses (4 cycles). In metastatic disease, continue until disease progression or unacceptable toxicity 14.